[HTML][HTML] A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer

CY Huang, DT Ju, CF Chang, PM Reddy… - Biomedicine, 2017 - ncbi.nlm.nih.gov
Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive
disease to review and possibly improve therapeutic treatment options. Surgery, radiation …

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Q Jiao, L Bi, Y Ren, S Song, Q Wang, Y Wang - Molecular cancer, 2018 - Springer
Protein tyrosine kinase (PTK) is one of the major signaling enzymes in the process of cell
signal transduction, which catalyzes the transfer of ATP-γ-phosphate to the tyrosine residues …

[HTML][HTML] Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer

Y Lei, W Guo, B Chen, L Chen… - Oncology …, 2018 - spandidos-publications.com
Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced‑stage …

Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial

AW Horne, S Tong, CA Moakes, LJ Middleton… - The Lancet, 2023 - thelancet.com
Background Tubal ectopic pregnancies can cause substantial morbidity or even death.
Current treatment is with methotrexate or surgery. Methotrexate treatment fails in …

Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics

BT Le, P Raguraman, TR Kosbar, S Fletcher… - … Therapy-Nucleic Acids, 2019 - cell.com
Cancer is one of the leading causes of death worldwide, and conventional cancer therapies
such as surgery, chemotherapy, and radiotherapy do not address the underlying molecular …

RETRACTED ARTICLE: The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC

X Li, X Zhang, C Yang, S Cui, Q Shen, S Xu - Cell Cycle, 2018 - Taylor & Francis
Statement of Retraction We, the Editors and Publisher of the journal Cell Cycle, have
retracted the following article: Xuehao Li, Xin Zhang, Chunlu Yang, Sui Cui, Qiming Shen …

Lung cancer survival among never smokers

A Casal-Mourino, L Valdes, JM Barros-Dios… - Cancer letters, 2019 - Elsevier
Lung cancer incidence among never smokers has increased in recent decades with 10–
30% of all lung cancers occurring in never smokers, where exposure to residential radon is …

MiR-450a-5p strengthens the drug sensitivity of gefitinib in glioma chemotherapy via regulating autophagy by targeting EGFR

Y Liu, L Yang, F Liao, W Wang, ZF Wang - Oncogene, 2020 - nature.com
Glioma reported to be refractory to EGFR tyrosine kinase inhibitor is the most common
malignant tumor in central nervous system. Our research showed the low expression of miR …

[HTML][HTML] Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor

F Wienen, R Nilson, E Allmendinger, D Graumann… - Biomaterials …, 2023 - Elsevier
Introduction Treatment of head and neck squamous cell carcinomas (HNSCC) by oncolytic
adenoviral vectors holds promise as an efficient anti-cancer therapy. The epidermal growth …

Craft of co-encapsulation in nanomedicine: a struggle to achieve synergy through reciprocity

S Bhattacharjee - ACS Pharmacology & Translational Science, 2022 - ACS Publications
Achieving synergism, often by combination therapy via codelivery of chemotherapeutic
agents, remains the mainstay of treating multidrug-resistance cases in cancer and microbial …